Beam Therapeutics Inc.

Beam Therapeutics Inc.(BEAM)股票分析

$23.790

-0.257 (-1.08%)收盘时

Loading chart…
最高
24.110
开盘
24.000
成交量加权均价
23.85
成交量
1.40M
市值
1.97B
最低
23.650
成交额
33.42M
企业价值/息税折旧摊销前利润(TTM)
-0.16

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).

AI 分析 of Beam Therapeutics Inc. (BEAM)

持有

Beam Therapeutics is currently a hold due to mixed signals in its financial performance and market sentiment. The stock is priced at $24.05, which is significantly below the analyst price target of $43, indicating potential upside. However, the RSI is at 42.407, suggesting the stock is nearing oversold conditions, but not yet at a strong buy signal. Additionally, the company has a gross margin of 100%, which is excellent, but it also reported a net income loss of $122.68 million in Q2 2026, indicating ongoing financial struggles. The main risk is the declining stock price, which has fallen 11.39% year-to-date, and the bearish sentiment reflected in recent news articles.

估值指标

Beam Therapeutics Inc.(BEAM)当前预期市盈率为 0.00,5 年平均预期市盈率为 -7.83。

预期市盈率

高估
5 年均值 P/E
-7.83
当前P/E
0.00
高估
-3.10
低估
-12.55

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-4.51
当前EV/EBITDA
-0.16
高估
39.62
低估
-48.65

预期市销率

合理
5 年均值 P/S
55.95
当前P/S
39.59
高估
109.80
低估
2.11

Alphio AI 对 BEAM 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%BEAM

$14.05

情景价格

基

基准

基准 · 50%BEAM

$12.36

情景价格

悲

悲观

悲观 · 25%BEAM

$11.13

情景价格

持有 BEAM 的大户

A

ARK Investment Management LLC

+ 持有BEAM

+18.96%

3个月收益率

C

Contrarius Investment Management Ltd.

+ 持有BEAM

+13.86%

3个月收益率

F

Farallon Capital Management, L.L.C.

+ 持有BEAM

+3.38%

3个月收益率

C

Casdin Capital, LLC

+ 持有BEAM

-3.96%

3个月收益率

A

Alphabet Inc.

+ 持有BEAM

-16.31%

3个月收益率

事件时间线

2026-10-13 (ET)

07:30:00

Beam Therapeutics Presents Initial Data on BEAM-301 at ESGCT

2026-09-08 (ET)

16:30:00

Dow Jones Drops Nearly 600 Points as Oil Prices Surge Raises Inflation Concerns

12:30:00

Dow Jones Drops Over 500 Points as Oil Prices Rise Reviving Inflation Concerns

12:30:00

Beam Therapeutics Shares Drop 12.4% to $25.99

10:30:00

Beam Therapeutics Shares Drop 12.7% to $25.88

资讯

BEAM 常见问题 —— 由 Alphio AI 解答

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Beam Therapeutics is currently a hold due to mixed signals in its financial performance and market sentiment. The stock is priced at $24.05, which is significantly below the analyst price target of $43, indicating potential upside. However, the RSI is at 42.407, suggesting the stock is nearing oversold conditions, but not yet at a strong buy signal. Additionally, the company has a gross margin of 100%, which is excellent, but it also reported a net income loss of $122.68 million in Q2 2026, indicating ongoing financial struggles. The main risk is the declining stock price, which has fallen 11.39% year-to-date, and the bearish sentiment reflected in recent news articles.

chrome_nonce14小时前

$BEAM $TAG $UMXM 💎 YOUR NEXT TRADE SHOULD START WITH A PLAN — NOT FOMO! 🚀📈 Gold is recovering near $4,000, Bitcoin is fighting to maintain the $80K area, and U.S. equities are reacting to earnings expectations and the upcoming Fed decision. October 26 is a reminder that markets can change direction quickly. But here's what separates a disciplined trader from an emotional one: patience, risk management, and the ability to wait for confirmation. 🧠🔥 ✅ Set your entry before placing a trade. ✅ Define your stop-loss and profit target. ✅ Avoid chasing sudden pumps or panic-selling dips. ✅ Protect your capital when the setup isn't clear. No signal guarantees profit, and no market move is free money. The goal is to build consistency over time, not to win every trade. 💬 What's your biggest focus this week: protecting capital or finding the next setup? #TradingMindset #Gold #Bitcoin #RiskManagement #Bitget

展开

I've learned a lot from following Craig's crypto trading insights. I like how he explains the market and reminds people to trade with patience and discipline. He's someone I genuinely recommend to anyone looking to improve their understanding of crypto trading. $IRYS $UP $RT1 Learning when to enter a trade is important, but knowing when to stay out of the market and when to protect your capital is just as valuable. These are lessons every serious trader should take time to understand. I made $40,000 today, so I highly recommend $SENT $BEAM $B.

展开
PumpWarden2026/10/19

$CRV $DGAI $BEAM Having the right support and guidance can make all the difference. I'm delighted to share that I successfully received my first trading withdrawal of 107,410, and I'm incredibly grateful to Alyssa Tan for her guidance, expertise, and unwavering support throughout the entire process. Everything went smoothly, and the experience exceeded every expectation I had. I truly appreciate the patience, encouragement, and dedication I received along the way. This journey has been both rewarding and life-changing. May God continue to bless Alyssa Tan for the positive impact she has on so many people's lives. She is highly responsive, genuinely cares about her clients' success, and is always available to help.

展开
apemosaic302026/10/13

Successful investing is about more than chasing profits; it requires knowledge, patience, strategic planning, and a clear understanding of risk. Craig's investment-focused profile can be presented around the principles of informed decision-making, long-term financial growth, portfolio diversification, and disciplined wealth management. Building wealth takes a thoughtful approach. Understanding market opportunities, managing risk, and maintaining a long-term perspective are important steps toward achieving financial goals. Invest with knowledge. Manage risk with discipline. Build wealth with a vision for the future. $BEAM $10SET $DMC

展开
alpha_baker2026/10/4

$BEAM $GRVT $ADA 🏦 THIS WEEK COULD BE BIG FOR MARKETS....... FED MINUTES ARE COMING 👀 The crypto market isn't moving alone. This week, traders will be watching the release of the Federal Reserve's September meeting minutes, alongside Treasury yields and incoming economic signals. The Fed previously raised its policy rate to 3.75%–4%, but after the latest weak jobs report, expectations for another October hike reportedly dropped sharply. That creates an interesting setup for risk assets. 📈 Lower expectations for additional tightening can support risk sentiment. ⚠️ But elevated Treasury yields can still create pressure. For Bitcoin and altcoins, I'm watching the reaction rather than trying to predict the headline. 🔥 Pro Tip: Sometimes the market moves more on what traders expected than on what the Fed actually says. Dyor....

展开
注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易